-
Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart FailureDB Mark, PA Cowper, KJ Anstrom et al. -
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedF Zannad, JP Ferreira, SJ Pocock et al.
-
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)P Joseph, K Swedberg, DP Leong et al.
-
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 StudyKosiborod M, Lam CSP, CVD-REAL Investigators and Study Group.
-
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failureNR Pugliese, F Paneni, M Mazzola et al.
-
The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) StudyIbrahim NE, Januzzi JL Jr.
-
Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk FactorsM Przewlocka-Kosmala, TH Marwick, H Yang et al.
-
Dapagliflozin for treating chronic heart failure with reduced ejection fractionNational Institue for Health and Care Excellence
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
